Cross-Sector entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Butterfly Network, the most common co-covered peer. We currently track 1 Cross-Sector story that mention HEPZATO KIT, all published on February 25, 2026.
1 verified story tracked
Last mentioned: Feb 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Butterfly Network, the most common co-covered peer. We currently track 1 Cross-Sector story that mention HEPZATO KIT, all published on February 25, 2026. Each carries 4 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HEPZATO KIT. Shared-story counts are live from our verified record — not editorial picks.
As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.
